EUCTR2017-002779-24-GB进行中（未招募）1 期
A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease. - Bisoprolol in COPD study (BICS)
niversity of Aberdeen0 个研究点目标入组 1,574 人开始时间: 2018年7月5日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,574
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Aged = 40 years.
- •-A smoking history of at least 10 pack years.
- •-An established predominant diagnosis of COPD (NICE Guideline definition: post bronchodilator FEV1<80% predicted, FEV1/FVC<0.7) receiving treatment as per local guidelines’.
- •-A history of at least two exacerbations requiring treatment with antibiotics and/or oral corticosteroid use in the previous year, based on patient report.
- •-Clinically stable with no COPD exacerbation for at least 4 weeks.
- •-Able to swallow study medication.
- •-Able and willing to give informed consent to participate.
- •-Able and willing to participate in the study procedures, complete study questionnaire.
- •-Able and willing to undergo spirometric assessment, able to perform an FEV1 manoeuvre as a minimum.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 800
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 770
排除标准
- •-A current sole respiratory diagnosis of asthma.
- •-Any diagnosis of asthma before the age of 40 years.
- •-A predominant respiratory disease other than COPD.
- •-Any significant disease/disorder which, in the investigator’s opinion, either puts the patient at risk because of study participation or may influence the results of the study or the patient's ability to participate in the study.
- •-Previous allocation of a randomisation code in the study or current participation in another interventional study (CTIMP or non-CTIMP).
- •-Already taking beta-blocker.
- •-Known or suspected hypersensitivity to beta-blocker.
- •-For women, current pregnancy or breast-feeding, or planned pregnancy during the study.
- •-Unable to perform spirometry (FEV1 manoeuvre).
- •-Current resting (5 minutes sitting) heart rate <60 bpm.
- •-Current resting (5 minutes sitting) systolic blood pressure <100mmHg.
- •-2nd, 3rd degree heart block on ECG (unless pacemaker in situ).
- •-Conditions for which beta-blocker use is a guideline recommendation, i.e. heart failure, or within the last year: myocardial infarction, acute coronary syndrome.
- •-Current tachyarrythmia or bradyarrhythmia (including sick sinus syndrome, sinoatrial block) requiring treatment.
- •-Current treatment with interacting drugs:
- •oheart rate limiting drug such as calcium channel blockers (diltiazem, verapamil), ivabradine,
- •oclass-I antiarrhythmic drugs (e.g. quinidine, disopyramide; lidocaine, phenytoin; flecainide, propafenone),
- •ocentrally-acting antihypertensive drugs (e.g. clonidine methyldopa, moxonidine, rilmenidine).
- •-Severe peripheral arterial occlusive disease, severe forms of Raynauds syndrome.
- •-Conditions that are known to be triggered by beta-blockers or beta-blocker withdrawal including myasthenia gravis, periodic hypokalaemic paralysis, pheochromocytoma, thyrotoxicosis and psoriasis/history of psoriasis.
研究者
相似试验
进行中（未招募）
1 期
TWICS - Theophylline with Inhaled CorticosteroidsEUCTR2013-001490-25-GBniversity of Aberdeen1,424
进行中（未招募）
不适用
A randomised, double blind placebo controlled trial to (A) assess the optimal vitamin K dosage for supplementation, and (B) to access whether complications of anticoagulation treatment will diminish by supplementation of vitamin K: VIKS-2A / VIKS-2B. - VIKS-2A / VIKS-2BEUCTR2007-004578-15-NLDutch Heart Foundation2,600
已完成
不适用
A study of AMLA extract to assess the antioxidant and rejuvenation potential in adults in a placebo controlled clinical trial.CTRI/2018/08/015157Acara Bioherb Pvt Ltd
已完成
4 期
A randomised, double blind placebo controlled trial to (A) assess the optimal vitamin K dosage for supplementation, and (B) to access wether complications of anticoagulation treatment will diminish by suppletion of vitamin K.Complicaties van behandelingBleedingThrombosis10064477NL-OMON30852eids Universitair Medisch Centrum2,600
已完成
不适用
Randomised, double-blinded placebo controlled trial of the use of tocolysis for a repeat external cephalic version after a failed version for breech presentation at termChildbirthPregnancy and ChildbirthOther assisted single deliveryISRCTN31614268HS R&D Regional Programme Register - Department of Health (UK)124